Recursion Pharmaceuticals, Inc. (RXRX) stock experienced a significant surge in pre-market trading on Tuesday, soaring 13.82%. The rally came after tech giant Nvidia disclosed that it maintained its investment in the medical AI company during the fourth quarter of 2024.
Nvidia's sustained backing of Recursion Pharmaceuticals has bolstered investor confidence in the company's prospects. Traders view Nvidia's continued investment as a vote of confidence in Recursion Pharmaceuticals' potential, fueling the pre-market rally.
The positive sentiment surrounding Recursion Pharmaceuticals was further amplified by Berkshire Hathaway's recent investment activities, including taking a new position in Constellation Brands. This move by the investment giant has injected optimism into the broader market, contributing to the stock's upward momentum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.